Department of Pathology, University of Massachusetts Memorial Medical Center, Worcester, Massachusetts.
Department of Pathology, University of Massachusetts Memorial Medical Center, Worcester, Massachusetts.
J Am Soc Cytopathol. 2021 Mar-Apr;10(2):135-140. doi: 10.1016/j.jasc.2020.08.008. Epub 2020 Aug 27.
Colposcopic endocervical brushing cytology (CEB) is more sensitive than endocervical curettage (ECC) for detecting squamous intraepithelial lesions. There are no data on performance of CEB for detecting endocervical adenocarcinoma.
A total of 151 patients were identified in a word search for "endocervical adenocarcinoma" in surgical pathology reports from January 2007 to June 2019. To measure sensitivity, reports of CEB or ECC samples within 1 year preceding the first surgical pathology diagnosis of at least endocervical adenocarcinoma in situ (AIS+) were examined. Specificity was measured in a cohort in which at least atypical glandular cells (AGC+) was reported in CEB or ECC.
Seven CEB preceding diagnosis of AIS were identified: 6 of 7 were positive or suspicious for AIS+. One of 7 was negative and it was negative on re-review. Three of 6 positive CEB cases used cell blocks with immunohistochemistry. Seventy ECC samples preceding diagnosis of AIS were identified: 40 of 70 were diagnosed as AGC+. The sensitivities of CEB and ECC for detecting AIS+ at a threshold of AGC+ are 86% and 57% (too few patients for statistics), respectively. For specificity, 12 of 18 CEB and 9 of 25 ECC reports with AGC+ were false positive by follow-up surgical pathology. The specificities of CEB and ECC are 99.4% and 99.9%, respectively.
Sensitivity of CEB for detecting AIS+ (86%) is at least as high as ECC (57%). Specificity of CEB is similar to ECC. Addition of a cell block to CEB may be useful. CEB appears to be an appropriate test for follow-up of atypical glandular cells reported on Papanicolaou tests.
阴道镜下宫颈内膜刷取细胞学(CEB)比宫颈内膜刮宫术(ECC)更能敏感地检测到鳞状上皮内病变。目前尚无关于 CEB 检测宫颈腺癌的性能数据。
通过在 2007 年 1 月至 2019 年 6 月的外科病理报告中搜索“宫颈腺癌”一词,共确定了 151 例患者。为了测量敏感性,检查了在首次外科病理诊断至少为宫颈内膜原位腺癌(AIS+)之前 1 年内的 CEB 或 ECC 样本的报告。特异性是在至少报告了非典型腺细胞(AGC+)的 CEB 或 ECC 队列中进行测量的。
在诊断 AIS 之前,发现了 7 例 CEB:7 例中有 6 例对 AIS+呈阳性或可疑。7 例中有 1 例为阴性,重新审查后也为阴性。6 例阳性 CEB 中有 3 例使用细胞块进行免疫组织化学检查。在诊断为 AIS 之前,发现了 70 例 ECC 样本:70 例中有 40 例被诊断为 AGC+。CEB 和 ECC 检测 AIS+的敏感性分别为 86%和 57%(患者数量太少,无法进行统计学分析)。对于特异性,在随访外科病理中,18 例 CEB 中有 12 例和 25 例 ECC 中有 9 例的 AGC+报告为假阳性。CEB 和 ECC 的特异性分别为 99.4%和 99.9%。
CEB 检测 AIS+的敏感性(86%)至少与 ECC(57%)一样高。CEB 的特异性与 ECC 相似。在 CEB 中添加细胞块可能是有用的。CEB 似乎是巴氏涂片检查报告的非典型腺细胞随访的合适检查。